SCID-hu mice provide an in vivo model for studying the events of normal intrathymic human T-cell development and differentiation. We injected SCID-hu mice with staphylococcal enterotoxins (SE) and determined their effects on the development and responsiveness of human T-cell populations defined by their expression of CD4 and CD8, and the type of Vg molecule in their T-cell receptors. After single intraperitoneal injections of SEB or SEE, we observed specific effects on thymic T cells expressing a cognate Vg T-cell receptor (TCR) (Vg 12.1 in the case of SEB-treated SCID-hu mice and Vg 8.1 in the case of SEE-treated mice) using both immunohistochemical staining of thymic frozen sections and flow cytometric analyses. An injection of SEB resulted in a 32% decrease in the total percentages of Vf3 12.1+ cells in thymic sections after 2 days, with the greatest effect seen in the medulla, without a demonstrable effect on V$5.2/5.3+ or Vg 8.1 + cells. Fluorescence-activated cell sorter analysis demonstrated that TCRhi thymocytes expressing a cognate HE THYMUS is a site of clonal deletion of self-T reactive T cells and the positive selection of T cells that are capable of recognizing antigens in the context of self-major histocompatibility complex (MHC).14 The process of clonal deletion to self-antigens has been studied in mice that constitutively express proteins derived from endogenous mammary tumor virus (MTV) genes (minor lymphocyte substance [MIS]; endogenous s~perantigens)~-l~ and in weanling mice exposed to repeated doses of staphylococcal enterotoxins (SE; exogenous superantigens).l17l2 These bacterial and virally encoded proteins are termed "superantigens" because their exposure to mature T cells results in a massive, polyclonal proliferative response of clonotypic T cells that express the same VP chain in their T-cell receptor (TCR).13-15 In contrast to the effect on mature, peripheral T cells, the exposure of immature T-cells in the thymus to endogenous or exogenous superantigens results in a marked reduction in the number of cells that express a cognate TCR-VP capable of binding to the respective superantigen compared with control mice that lack expression of the endogenous superantigen* or who have not been exposed to SE.12 Intrathymic transfer of 
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sorted, mouse T-cell populations at different stages of development indicated that positive selection begins at the CD4+8+ TCR'O blast stage, resulting in increased frequency of cells committed to the CD4 or CD8 lineage that express intermediate amounts of TCR, whereas negative selection occurs at the same phase of the transition of these cells to virgin CD4 or CD8 thymic T cells expressing high levels of TCR.4 While the mitogenic effect of exogenous superantigens has been observed in vitro using human T cells,1°J6 the processes of intrathymic clonal deletion and the induction of tolerance have not been extensively studied. Selective deletion of Vg 5.2/5.3+ thymocytes and Vp 8.1+ thymocytes after the addition of SED or SEE to human thymocytes in organ culture with mouse thymi has been recently reported. 17 Thymocytes from SCID-hu mice engrafted with hematopoietic cells and thymic stroma from different fetal donors are tolerant when challenged in vitro to EpsteinBarr virus (EBV)-transformed lymphoblastoid cells from either fetal donor, and thymocytes reactive to the donor of the hematopoietic cells have been deleted.'* To date, no evidence for clonal deletion in response to endogenous superantigens occurs in humans, because T cells expressing all the different Vp genes in their TCR appear to be present in roughly equal frequencies in randomly selected individua l~.~~ Understanding the mechanism of clonal deletion will likely be important in furthering our understanding of autoimmune diseases that represent a failure to eliminate self-reactive T-cell populations; in graft-versus-host disease seen in allogeneic bone marrow transplantation (BMT); and in augmenting the graft-versus-leukemia phenomenon in autologous BMT. We have used SCID mice engrafted with fragments of human fetal thymus (SCID-hu)20,21 as a model system to study the effects of exogenous superantigens on the intrathymic maturation of human T cells. We find that clonal deletion of human T cells expressing a cognate TCR occurs in SCID-hu mice that have been exposed to a single or to multiple doses of SE. We have observed both antigen-specific anergy and a proliferative 
MATERIALS AND METHODS
SCID and SCID-hu mice. C-B 17 scidlscid mice were obtained from Leonard Shultz (Jackson Labs, Bar Harbor, ME) and maintained under specific pathogen-free conditions in the animal facility of the Division of Radiobiology. The mice received a suspension of Trimethoprim sulfamethoxidole in their drinking water three times a week. SCID-hu mice were created using fetal tissues from 16-to 20-week gestations (obtained after therapeutic abortions), as previously Use of fetal tissue for research purposes was consented to by the respective patients after their decision to undergo the operative procedure and approved by an institutional review board. Small fragments of fetal thymus and liver (a source of hematopoietic stem cells) were placed beneath the left kidney capsule. Engrafted SCID-hu mice showed the growth of human thymic tissue to more than 100 times the original volume in more than 90% of the cases and the appearance of CD4+8-and CD4-8+ cells in the peripheral blood of the mouse. Approximately 15 SCID mice were engrafted with fragments from each fetal thymus; in each individual experiment, both the treated and control mice were taken from a group of mice that had been engrafted with tissue from the same fetus. The blood of SCID-hu mice was obtained by quickly bleeding the mice (after they had been killed) into tubes containing 5 mmol/L HEPES-buffered Hanks Balanced Salt Solution (HBSS), pH 7.4, containing 0.02% sodium azide and 5% vol/vol heat-inactivated newborn calf serum (HBSS/NCS) and 10 U/mL heparin. The mononuclear cell fraction was obtained after centrifugation over a Ficoll step gradient.
SEB was purchased from Sigma Chemical Co (St Louis, MO). SEE, and SEC3, SED were purchased from Toxin Technology, Inc (Madison, WI). SEB and SEE were reconstituted with distilled water to concentrations of 5 mg/mL and stored in aliquots at -20°C. SCID-hu mice received intraperitoneal (IP) injections of SEB or SEE diluted in HBSS/NCS; control mice received injections of HBSS/NCS alone. Some SCID-hu mice received multiple injections of enterotoxins on Monday, Wednesday, and Friday of each week for a total of seven to nine doses before being killed for analysis. SE administration in doses up to 20 pg did not result in any discernable ill effects on the health of the SCID-hu mice.
Immunohistochemical analysis of Vp expression on thymic grafts from SCID-hu mice. Tissue samples were frozen in Tissue-Tek OCT embedding medium (Miles Scientific), stored at -7O"C, and cut into thin sections. Immunohistochemistry was performed using a biotin-streptavidin technique previously described.z Briefly, cryostat sections were fixed in acetone at 4°C for 10 minutes." Sections were incubated with unlabeled monoclonal antibody (MoAb) to Vp 5.2 + 5.3, Vp 8.1, or Vp 12.1 (T Cell Sciences, Cambridge, MA). Sections were sequentially incubated with appropriate dilutions of biotin conjugated goat antimouse (Jackson Immunoresearch Laboratories, Inc, West Grove, PA) and horse radish peroxidase-conjugated streptavidin (Jackson Labs). Each incubation was followed by washing in phosphate-buffered saline (PBS). The peroxidase reaction was developed with 3% diaminobenzidine and sections were lightly counterstained with methylene blue. The percentages of medullary and cortical thymocytes that expressed a particular Vp TCR were determined by counting the number of positive cells per 500 total thymocytes in high-power fields of cortex and medulla; the percentage of positive cells in the whole thymus represents a mean of the values obtained for the cortex and the medulla, as they each occupied approximately the same area on the cryostat section.
Flow cytometric analysis of human thymocytes obtained from Enterotoxin-induced proliferation of thymocytes from SCID-hu mice. Single-cell suspensions from thymus grafts were obtained sterilely from treated or control mice were washed two times in plain Iscove's modified Dulbecco's medium (IMDM; Sigma). The cells were resuspended to 5 x 106/mL in IMDM supplemented with 2% vol/vol normal mouse serum, 100 U/mL penicillin, 100 pg/mL streptomycin, 1 pg/mL indomethacin, 5 x 10-5 mol/L 2-mercaptoethanol, 1 mmol/L sodium pyruvate, 5 pg/mL transferrin, 5 ng/mL sodium selinite, 5 pg/mL insulin, and 2 mmol/L glutamine. Cells (5 x 105) in 100 pL were added to wells in round-bottom tissue culture plates (Costar, Cambridge, MA), along with selected toxin (Toxin Technology) at a final concentration of 1 pg/mL. Cells were incubated for 2 days at 37°C and then pulsed with 1 pCi 3H-thymidine (Amersham, Arlington Heights, IL) for an additional 18 hours. Cells were harvested by aspirating the cell suspension onto glass fiber filters and washing the filters with distilled water. Each experimental point represents the mean of 8 to 12 wells. (Fig 1). A larger + cells was seen (not shown). Thymic xenografts from untreated SCID-hu mice contained human thymocytes whose numbers varied over a 2 log range, with a mean of 83 x I@ ( f S D of 87 x lo"); administration of 2 pg SEB did not result in any significant decrement in the mean number of cells compared with control mice injected with buffer alone (Fig 2A) . Injections of more than 2 pg of SEB resulted in a more than 50% decrease in the average numbers of viable human thymocytes that could be recovered from treated SCID-hu mice compared with SCID-hu mice engrafted with the same fetal thymic tissue, but not exposed to SE (data not shown). The remainder of experiments described b&w used a standard dose of 2 pg SEB.
To quantify the effects of SE on levels of TCR expression in SCID-hu thymocytes, we used multiparameter flow cytometric analysis to assess the expression of CD4, CD8, 181 SEB-treated SCID-hu mice, the mean percentage (2SD) of CD4'8-cells in untreated mice was 12% f 7.5% and remained stable over 6 days (mean value at 6 days of 13% 2 1.7%), whereas the fraction of CD4-8+ cells in control mice was 5.2% f 5.6% and remained stable over 6 days (mean value at 6 days of 4.7% f 0.3%). A representative experiment is shown in Fig 2B, 3) . The electronic gate used to delimit the Vp+ cells from the negative population was defined by the staining profile of thymocytes using an FITC-labeled control mouse IgG for Vp expression by flow cytometry, the percentage of Vp 12.1+ cells was 3.2% in the graft from the untreated SCID-hu mouse, declined to 1.8% in a graft from a SCID-hu mouse 2 days after SEB administration, and then increased to 3.8% 4 days after SEB administration. When an electronic gate was set to count the cells expressing the highest level of Vp 12.1 (eg, the TCRhi cells as shown in Fig 3) , there was an even greater effect of SEB administration on Vp 12.1 expression: a 68% decline from 2.5% positive cells in control mice to 0.8% positive cells in grafts from SCID-hu mice 2 days after SEB administration. Because the most pronounced effect of SEB administration was seen on cells expressing the highest levels of TCR and in medullary cells, both characteristics of thymocytes at the most mature stage of intrathymic development, we examined the levels of TCR expression on thymocytes in the (phenotypically mature) CD4+8-and CD4-8+ subpopulations. Because the total number of human thymocytes varied significantly among different thymic xenografts (Fig 2A) , it was difficult to compare the effect of SE administration on the absolute numbers of Vp+ T cells among SCID-hu mice that received different treatments. We therefore calculated the percentage of cells in the CD4+8-and CD4-8+ thymic subpopulations expressing Vp 5.215.3, Vp 8.1, or Vp 12.1 from control mice and in mice that had received a single injection of SEB. The staining intensity for Vp expression in these subpopulations was generally similar to the Vphi cells shown in Fig 3. Incubating the thymocytes with a control, FITC-labeled mouse IgG, in combination with CD4 and CD8 antibodies, resulted in less than 0.02% of CD4-8+ or CD4+8-cells, with a fluorescein signal greater than the lower gate for fluorescein-positive cells indicated in Fig 3 (not shown) after SEB administration (P < .2 to P < .001). Multiple injections of SEB resulted in a 60% decrease in the fraction of Vp 12.1+ CD4+8-thymocytes compared with control SCID-hu mice (P < .05) and a 120% increase in Vp 5 2 / 5 3 CD4-8+ thymocytes (P < .05) (Fig 5) . The differences observed after multiple injections of SEB occurred without significant effects on the total numbers of thymocytes recovered from SCID-hu mice. Lower doses of SEB pro- 
effects on Vp expression, but of a smaller magnitude, than the standard doses of 2 pg that we have used throughout the rest of this work.
Effects of SEE administration on V p TCR, CD4, and CD8 expression on SCID-hu thymocytes. We next studied the effects on human T-cell development in SCID-hu mice of administering SEE, a staphylococcal enterotoxin that is known to have mitogenic effects on mature human T cells expressing TCR Vp 8.1. The effect of a single 0.5 pg SEE injection was to increase the fraction of cells in the CD4+8-and CD4-8+ populations to 20% f 3.7% and 7% to 1.2%, respectively, in mice that had been treated 7 days earlier with SEE, compared with 13% f 4% and 4% f 1.4%, respectively, in untreated control SCID-hu mice (P < .001 and P < .001, respectively), and caused a gradual, slight decrease in the average numbers of thymocytes that were recovered from the thymic xenografts: 98. Fig 8) .
Development of antigen-specif c anergy in thymocytes from SCID-hu mice. The effect of a single injection of SE was transient and partial with respect to the elimination of T l"L cells expressing the cognate TCR; 4 days after SEB injection the percentages of CD4+8-and CD4-8+ T cells expressing Vp 12.1 had returned to control values. We tested whether thymocytes that expressed the cognate TCR after SE administration were capable of a proliferative response when rechallenged to the corresponding SE in vitro. Thymocytes obtained 4 days after from SEB administration to SCID-hu mice failed to proliferate in vitro in the presence of SEB, but had a normal proliferative response to SEE and SEC3 and an intermediate proliferative response to SED (Fig 9) .
Analysis of human T cells in the blood of SCID-hu mice. The effect of SEB administration was to cause a twofold increase in the small percentages of phenotypically mature (CD4+ and CD8+) human T cells when the blood of SCID-hu mice was analyzed by flow cytometry (Table 1) . Within the CD4+ and CD8+ subpopulations, rare cells expressing specific Vp receptors could be detected in control mice and those that had been exposed to SEB. Three to 4 days after SEB injection, we observed fourfold increases in the fractions of Vp 12.1+ CD4+8-and sixfold increases in Vp 12.1+ CD4-8+ cells (P < .05) compared with the mean percentages of CD4+ and CD8+ cells expressing Vp 12.1 from control SCID-hu peripheral blood lymphocytes (PBL) ( Table 1) . Significantly increased percentages of T cells expressing Vp 5.215.3 and 8.1 were not seen after SEB administration. Multiple injections of SEB did not result in larger percentages of detectable Vp 12.1 cells in the circulation of the mouse. When the blood of SCID-hu mice that had received injections of 0.5 pg of SEE 5 days earlier was analyzed for Vp TCR, CD4 and CD8 expression, we observed that the mean percentages t SD of CD4+8-and CD4-8+ cells increased to 0.35% f 0.06% and 0.68% t 0.006%, respectively, in SEE-treated SCID-hu mice, from 0.195% & 0.02% and 0.47% +: 0.14%, respectively, in untreated, control SCID-hu mice. The percentage of Vp 8.1+ CD4+8-and CD4-8+ cells increased from 0.012% and 0%, respectively, in control SCID-hu mice, to 0.024% and 0.16% 5 days after SEE administration. The CD4+8-and CD4-8+ cells present in the peripheral blood of SCID-hu mice following SE administration had forward scatter profiles characteristic of activated or proliferating lymphocytes, and were larger than those of the human T cells in the blood of untreated SCID-hu mice (Fig 10) . 5.6%, respectively. Despite these variables, the percentages of CD4+8-and CD4-8+ cells expressing a given Vp chain from control mice were remarkably constant, as were the qualitative effects of SE on cells expressing the cognate TCR receptor in SCID-hu mice engrafted with thymic tissue from different fetal donors. Some of the variation we observed in the quantitative effects of SE on T cells in the SCID-hu system may be due to differences in the HLA haplotype of the fetal tissue xenograft and a consequent variation in the affinity of SE binding to class I1 molec u l e~~~~~~; the size of the graft; the gestational age of the fetus; the age of the graft; or the relative percentages of single-positive versus double-positive T cells. The second technical point is that an effect of SE in this system reflects an effect on the cellular physiology of developing thymocytes rather than modulation or blocking of surface TCR. Control experiments demonstrated that preincubation of human thymocytes with SEB for 30 minutes at concentrations from 0.005 to 0.5 p,g/mL had no effect on the subseauent bindine of anti-VB 12.1 TCR specific anergy on thymocytes obtained from SE-treated mice; and (4) an increase in the numbers of T cells in the peripheral blood of SE-treated SCID-hu mice. Before discussing the specific effects of SE in this system, two technical points deserve comment. First, the fetal tissue used to engraft these mice was heterogeneous, varying in terms of the gestational age of the tissue (16 to 23 weeks), and there were cytogenetic abnormalities (approximately 50% of fetuses had prospectively identified trisomy, of which the majority involved chromosomes 21 or 18). The size of the thymic xenografts varied inversely with the gestational ages of the fetal tissue used for graftingB and varied directly with the time between the transplantation of the fetal tissue elapsed and its use in the experiments described herein. The total number of thymocytes that could be obtained from a single thymic xenograft in an untreated SCID-hu mouse varied over 2 logs, between 2.4 X lo6 and 360 X lo6, with a mean value of 83 x lo6 f 86 X lo6 in experiments involving SEB. When analyzed by flaw cytometry, the ratio between CD4+8-and CD4-8+ cells was close to, or slightly above, 2, a value consistent with the relative percentages of CD4+ and CD8+ cells in the blood of young children. There was considerable variability in the percentages of CD4+8-and CD4-8+ cells with ranges of 3.3% to 41.6% and 1.6% to 32%, respectively; and mean values f SD of 12.2% f 7.5% and 5.2% f " antibody (not shown j, indicating that modulaiion or masking of surface TCR associated with the binding of SE could not account for the specific deletion of Vp 12.1+ CD4+8-cells we observed. Additionally, the greatest effect of SEB in terms of antigen-specific anergy and deletion of clonotypic T-cell populations was seen 24 to 96 hours after intraperitoneal injection, whereas thymocytes obtained 6 hours after SEB administration expressed Vp 12.1 at the same (or higher) level as thymocytes from untreated SCID-hu mice, and had a normal (or enhanced) proliferative response to SEB in vitro. Additionally, it is unlikely that masking or capping of surface TCR by SEB could account for the decrease in the cortical Vp 12.1+ cells we observed in thymic froien sections after SEB administration (Fig 1) .
One effect of SE administration was to cause a 35% to 52% decrease in the percentages of thymocytes expressing high levels of the cognate TCR, seen most clearly in the CD4+8-subpopulation. Multiple injections of SE resulted in a 49% to 60% reductions in the percentage of CD4+8-cells expressing the cognate TCR+, with a less pronounced effect on the CD4-8+ subpopulation. Although these deletions were incomplete, they were reproducible in different experiments and statistically significant compared with untreated SCID-hu mice, with P values of less than .05. The effect on thymic populations expressing a specific TCR varied according to the SE administered, with SEB producing a deletion of Vp 12.1+ cells and SEE resulting in a decrease in Vp 8.1+ CD4+8-cells. The effect after a single injection was transient and likely related to the gradual decline in the intrathymic levels of SE antigen. Although the average number of thymocytes in the xenografts remained constant after SEB administration (Fig 2A) , the significant heterogeneity among the size of the grafts prevented a direct comparison of the absolute numbers of T cells expressing a particular Vp TCR. To compare data obtained from grafts with widely different numbers of thymocytes, the effect of SE on thymocytes expressing the cognate Vp TCR has been presented herein in terms of the percentages of CD4+8-or CD4-8+ subpopulations that expressed the same Vp TCR. The average numbers of CD4+8-or CD4-8+ thymocytes expressing a cognate Vp TCR can be calculated based on the mean number of thymocytes in a xenograft and the mean percentage of cells in the CD4+8-or CD4-8+ subpopulations. For example, control SCID-hu mice had xenografts that contained an average of 83 x 106 cells, of which an average of 368,000 were Vp 12.1+ CD4+8-cells. One day after SEB administration, the thymic xenografts contained an average of 89 x lo6 cells, of which an average of 148,000 were Vp 12.1+ CD4+8-. Similarly, the average control graft contained 128,000 Vp 12.1+ CD4-8+ cells, whereas the average The qualitative effect of multiple injections of SE on human T-cell development was similar to what has been reported in murine systems (in which neonatal mice received multiple SEB injections of up to 100 kg, and deletion of 58% of the total population of mouse thymocytes expressing the cognate Vp TCR occurred),12 and in mouse thymic organ cultures, in which the addition of SEB to the culture media resulted in the deletion of 45% to 93% of cells expressing the cognate TCR after 4 days.3I However, the magnitude of the reduction of human T cells of mature phenotypes expressing the cognate Vp TCR was less than that seen in mice, in which case multiple injections of 100 pg SEB resulted in the deletion of more that 90% of the mature (cortisol-resistant) T cells expressing the cognate TCR.l2 These differences may reflect a lower efficiency of antigen presentation in the SCID-hu thymic xenografts, heterogeneity of the T-cell population expressing the cognate TCR such that some of the human thymic T cells fail to interact with the relevant SE or the lower doses of SE that we have used in this study compared to earlier studies that described the effect of SE on murine T-cell development, or other, undefined factors in this system. Some of the sequela of administering SE to SCID-hu mice may also reflect an indirect action of cytokines released by T cells that have bound SE. The addition of SE to short-term human thymocyte cultures at concentrations of less than 1% of what was injected into SCID-hu mice described in this study results in the deletion of more than 90% of T cells expressing the cognate TCR (Waller et al, in preparation) , indicating that intrinsic resistance of human T cells to the effects of SE is unlikely. In view of the significant deletions observed after the administration of much smaller doses of SE, human thymic T cells appear to be at least as sensitive to the effects of exogenous superantigens as murine thymocytes.
In view of the lack of any known endogenous superantigen in human^,'^,^^ the relevance of the present work to understanding normal T-cell development and pathophysiology is in elucidating the sequence of events that likely occur during clonal deletion of CD4+8-T cells in response to self-antigens presented intrathymically. The failure of For personal use only. on September 24, 2017. by guest www.bloodjournal.org From such deletion (or anergy) to occur would result in the development of populations of mature, autoreactive T cells, and may be relevant to autoimmune disorders, graft-versushost disease, and a graft-versus-tumor effect in BMT recipients.
The second effect on T cells that we have observed using this system is a deletion of CD4-8+ cells expressing high levels of the cognate TCR accompanied by a relative expansion of CD4-P cells expressing intermediate levels of the cognate TCR after a single administration of SE. In SCID-hu mice that received SEB, we noted a significant and sustained increase in the mean percentages of CD4-P cells that expressed Vp 12.1 2 to 4 days after SEB administration and a sharp increase in the mean percentages of CD4+8-and CD4-8+ cells that expressed Vp 5.2153 and Vp 8.1 6 to 7 days after SEB administration (Fig  4) . Analysis of the density profiles of the Vp 5.2/5.3+ and Vp 8.1+ cells at 6 to 7 days did not indicate a significant expansion of CD4+8-or CD4-8+ cells expressing low levels of TCR, as was the case in the expansion of the CD4-8+ Vp 12.1+ population at 2 to 4 days (data not shown). The effect of an injection of SEB on Vp 5.2/5.3+ and Vp 8.1+ cells may represent the activity of impurities in the SEB preparation, or an unanticipated effect of SEB on other T-cell populations. In mice, SEB administration leads to a transient increase in CD4+8-and CD4-8+ cells expressing the cognate TCR in peripheral lymphoid organs. 15 In the human thymic xenografts we have studied, blast cells expressing the cognate TCR were only observed in the TCRl0 CD4+8+ populations, whereas there was a concomitant transient accumulation of TCRL0 CD4%+ cells and deletion of TCRhi CD4-8+ cells after the injection of a single dose of SE (Waller et ai, in preparation) .
A third effect of SE administration was that the thymocytes obtained more than 6 hours after SE administration failed to proliferate in vitro when cultured in the presence of the same SE to which they had been exposed in vivo (Fig  9) . The proliferative response of thymocytes from SEtreated SCID-hu mice was normal when they were cultured with other SE, indicating that the anergy observed in vitro was antigen-specific. The percentage of phenotypically mature thymocytes expressing Vp 12.1+ was equal to (or greater) than that in control mice levels 72 to 96 hours after SEB administration (Fig 4) , whereas thymocytes exposed in vivo to SEB remain anergic to subsequent exposure to SEB in vitro. Both clonal deletion and clonal anergy as mechanisms of antigen-specific tolerance have been described in Mls-lb(MTV-) mice that received indirect or direct intrathymic transfer of Mls-la(MTV+) ~e l l s , 3~,~~ and clonal anergy has been seen in mice immunized with either the endogenous superantigen MlsIMTV or SEB. Mls-lb mice immunized with Mls-la+ cells develop a Mls-la-specific anergy when subsequently challenged with Mls-la in an in vitro proliferation a~say.3~ T cells from mice immunized with SEB develop a specific anergy to the mitogenic effects of SEB in an in vitro proliferation assay.15,36,37 Clonal deletion and clonal anergy may be mediated through different mechanisms with deletion (in the case of Mls-la), the consequence of intrathymic antigen presentation of MTV gene products by CD5+ B cells, and clonal anergy resulting from antigen presentation by dendritic cells.34 Our data show that clonal deletion occurs in the human thymus in the presence of SE, and support the conclusion that clonal anergy can be observed in human thymocytes obtained from SCID-hu mice exposed in vivo to SE. The brief period during which we have observed clonal deletion in vivo (1 to 2 days) compared with the longer duration of anergy (1 to 7 days) indicates that the failure of cells to proliferate in vitro after in vivo exposure to SE was not a consequence of the absence of cells expressing the relevant cognate Vp TCR at the latter time points (compare Figs 4, 7, and 9). The different kinetics of deletion and anergy in this system may represent either (1) the intrathymic presentation of SE by the same antigen-presenting cells (APC) over the 7-day period, such that APC induced clonal deletion when high concentrations of antigen were present (days 1 and 2) and clonal anergy when lower amounts of bound antigen were present (days 3 to 7), or (2) antigen presentation by different types of cells: APC with a low binding affinity for SE, or a rapid catabolism of bound SE, that induce clonal deletion when intrathymic concentrations of SE are high; and a second class of APC with high binding affinity for SE (dendritic cells3*) or slow catabolism of bound SE that induce clonal anergy when intrathymic antigen concentrations are low. An alternative interpretation of the data from SCID-hu mice is suggested by the fact that the SE-induced deletion in vivo was never complete, and did not exceed 50% at 1 to 2 days after a single injection of SE. It is possible that within the cognate Vp TCR+ population there exist two discrete subsets of cells: those that interact with SE in vivo and are deleted, and those that fail to interact with SE. Although the total numbers of cells expressing the cognate Vp TCR were at normal or increased levels 3 to 7 days after SE administration (Figs 3,4,  and 7) , the unresponsive subset of cognate Vp TCR+ cells could have emerged as a greater fraction of the total cognate Vp TCR+ population, such that the overall proliferative response of these cells in vitro to SE was substantially less than cells from thymus grafts that had not been exposed to SE. The high efficiency of SE-induced deletion of human thymocytes expressing the cognate Vp TCR in vitro (Waller et ai, in preparation) makes the existence of two populations of thymocytes expressing the cognate Vp TCR with different responsiveness to SE in vivo unlikely. Thus, SE-treated SCID-hu mice should be an interesting model system in which to study the mechanism by which developing human T cells are tolerized to ~elf-antigens.~.~~
The fourth effect of SE administration was that T cells with a mature phenotype, present in the peripheral blood of the SCID-hu mice, increased substantially in response to SE administration. The effect was transient, occurring 3 to 4 days after SE injection ( Table 1) . A mitogenic effect has been described after in vitro stimulation of human T cells by SE,10J3,16,40 and for Vp 3+, 8.1+, 8.2+, and 8.3+ murine cells by SEB. 12 The increase in circulating human T cells could be due to (1) the egress of increased numbers of T cells from the thymus, (2) a transient increased intravascular survival and accumulation of T cells, (3) an intravascular proliferation of human T cells, or (4) some combination of these factors. While the numbers of detectable human T For personal use only. on September 24, 2017. by guest www.bloodjournal.org From cells expressing any specific Vp TCR in the blood of SCID-hu mice were very small, we observed a reproducible, threefold to sixfold increase in peripheral T cells bearing the cognate TCR (Table 1) 3 to 4 days after SE administration compared with control mice. This was most significant in the CD4+8-subpopulation and occurred at a time when the corresponding populations of thymic T cells expressing the cognate TCR were either decreased (the CD4+8-subpopulation) or increased (the CD4-8+ subpopulation) relative to the same populations in control mice that had not been exposed to SE (Figs 4 and 7) . It seems unlikely that the larger number of circulating TCR+ cells observed after SE administration was due to a threefold to sixfold increased thymic production of these cells. We have no data on the intravascular survival of human T cells in SCID-hu mice, but do note that human cells do not accumulate in the blood of SCID-hu mice to any significant degree, despite what we presume to be constant thymic production of T cells. The absolute numbers of human T cells in the blood of SCID-hu mice observed in this study were small, as the CD4+8-and CD4-8+ subpopulations combined comprised less than 1.5% of the low-density mononuclear cells in the blood of SE-treated animals ( Table 1 ) and represented less than 70,000 circulating human T cells (1.5% X 1.5 mL blood/mouse x 3 x lo6 mononuclear cells/mL), whereas the number of peripheral CD4+ or CD8+ human T cells expressing any particular Vp TCR was less than 4,000 cells/mouse. One explanation for the observed increase in the numbers of TCR+ cells in the peripheral circulation of SE-treated SCID-hu mice is that SE was acting as a mitogen for the small numbers of human T cells expressing the cognate TCR normally present in the peripheral blood of SCID-hu mice. This hypothesis was supported by a flow cytometric analysis of the size of the human T cells in the peripheral blood of SCID-hu mice, which suggested that T cells from SE-treated mice, being larger than those present in control mice, were activated and/or proliferating (Fig The relatively rare human T cells in the blood of SCID-hu mice (engrafted with human fetal thymic and liver tissue) proliferate in vitro in response to mitogens, although most of these T cells are CD45Ra+ and their activation by phytohemagglutinin (PHA) is less efficient than the activation of normal human PBL! I In contrast to the technique of engrafting fragments of fetal tissue into SCID mice we have used in this study,2°,21 transplantation of EBV-human PBL intraperitoneally into SCID mice42 or human umbilical cord blood" leads to the gradual accumulation of CD45Ro+ human T cells that are mitotically active in vivo but anergic in vitro when challenged with SCID spleen cells, PHA, or anti-CD3 (in the absence of exogenous interleukin-2)?3
10).
The differences between the functional state of human T cells in mice created using these two different methods of creating scid mice/human chimeras presumably reflects the different natural histories of T cells that develop within a thymus xenograft in a scid mouse compared with postthymic T cells injected into a scid mouse.
Taken together, these data support the affinity model for intrathymic T-cell maturation. Once the TCR is expressed on the cell surface, the binding of antigen to the TCR may result in either positive selection or clonal deletion. When thymocytes expressing high density of TCR bind to an antigen on a APC with high affinity, cell death occurs due to clonal deletion."" On the other hand, it has been postulated that a similar type of low-affinity interaction, involving fewer numbers of TCR bound to antigen molecules on APC, may result in positive selecti0n.4~ SE presented to CD4+8+ (double-positive) cells expressing the cognate TCR would be expected to be mitogenic, because of the small numbers of cognate TCR expressed on the surface that are available for SE binding. As double-positive cells begin to differentiate and express larger amounts of TCR, the effect of SE binding would vary according to the pathway along which they had differentiated. We see different effects of the intrathymic presentation of SE to CD4+8-and CD4-8+ cells expressing the cognate TCR, perhaps because SE has a specific affinity for class I1 HLA molecules,29~30~46~47 and the affinity of T cells expressing the CD4 coreceptor/TCR complex to SE in the presence of class I1 HLA on APC would be higher than the affinity of T cells expressing only the CD8 coreceptor/TCR complex to SE on APC.@ In both the CD4 and CD8 pathways, the single-positive, TCRhi cells would be deleted, either due to the larger number of surface TCR engaged and/or loss of immediate progenitors. Based on this model, we would predict that negative intrathymic selection occurs late in intrathymic development, at a time when thymocytes have expressed high levels of TCR; positive selection occurs at earlier stages of T-cell development associated with lower levels of surface TCR.4 The availability of an in vivo model for human T-cell development will allow direct testing of some aspects of this model, and a direct comparison between the events of T-cell development occurring in mice (and other animals) and in humans.
